CVRx, Inc. (CVRX): Price and Financial Metrics

CVRx, Inc. (CVRX): $20.68

0.03 (+0.15%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

CVRX Price/Volume Stats

Current price $20.68 52-week high $33.13
Prev. close $20.65 52-week low $8.38
Day low $20.49 Volume 1,529
Day high $20.75 Avg. volume 153,883
50-day MA $23.81 Dividend yield N/A
200-day MA $19.08 Market Cap 432.79M

CVRX Stock Price Chart Interactive Chart >

CVRX POWR Grades

  • CVRX scores best on the Sentiment dimension, with a Sentiment rank ahead of 96.43% of US stocks.
  • CVRX's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
  • CVRX's current lowest rank is in the Momentum metric (where it is better than 4.37% of US stocks).

CVRX Stock Summary

  • CVRX INC's stock had its IPO on June 30, 2021, making it an older stock than just 6.18% of US equities in our set.
  • With a year-over-year growth in debt of 8,591.43%, CVRX INC's debt growth rate surpasses 99.93% of about US stocks.
  • As for revenue growth, note that CVRX's revenue has grown 85.56% over the past 12 months; that beats the revenue growth of 94.84% of US companies in our set.
  • Stocks that are quantitatively similar to CVRX, based on their financial statements, market capitalization, and price volatility, are SXTC, HYW, ORMP, CHNR, and COLB.
  • CVRX's SEC filings can be seen here. And to visit CVRX INC's official web site, go to www.cvrx.com.

CVRX Valuation Summary

  • CVRX's EV/EBIT ratio is -14.3; this is 197.95% lower than that of the median Healthcare stock.
  • CVRX's price/sales ratio has moved down 67.2 over the prior 30 months.

Below are key valuation metrics over time for CVRX.

Stock Date P/S P/B P/E EV/EBIT
CVRX 2023-12-29 18.6 7.9 -15.4 -14.3
CVRX 2023-12-28 19.5 8.3 -16.1 -15.1
CVRX 2023-12-27 18.2 7.7 -15.0 -13.9
CVRX 2023-12-26 18.4 7.8 -15.2 -14.1
CVRX 2023-12-22 14.8 6.3 -12.2 -11.0
CVRX 2023-12-21 15.0 6.4 -12.4 -11.2

CVRX Price Target

For more insight on analysts targets of CVRX, see our CVRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.67 Average Broker Recommendation 1.25 (Strong Buy)

CVRx, Inc. (CVRX) Company Bio


CVRx, Inc. develops an implantable technology for the treatment of high blood pressure/hypertension and heart failure patients. It offers BAROSTIM NEO, a neuro-modulation therapy that triggers the body's natural reflex to regulate blood pressure and the underlying causes of the progression of heart failure, which is delivered through a long-lasting implant system, and customized to each patient's individual therapy needs. The company serves patients and healthcare professionals. CVRx, Inc. was incorporated in 2000 and is based in Minneapolis, Minnesota. It has operations in the United States, the United Kingdom, the Netherlands, Italy, Germany, and internationally.


CVRX Latest News Stream


Event/Time News Detail
Loading, please wait...

CVRX Latest Social Stream


Loading social stream, please wait...

View Full CVRX Social Stream

Latest CVRX News From Around the Web

Below are the latest news stories about CVRX INC that investors may wish to consider to help them evaluate CVRX as an investment opportunity.

CVRx to Present at the 42nd Annual J.P. Morgan Healthcare Conference

MINNEAPOLIS, Dec. 27, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024. The Company is scheduled to present at 3:45pm Pacific Time the same day via webcast. A live audio webcast of the c

Yahoo | December 27, 2023

CVRx (CVRX) Moves 24.2% Higher: Will This Strength Last?

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo | December 27, 2023

CVRx receives FDA approval for expanded labeling of Barostim

U.S. annual market opportunity increases based on real world adoption and strength of long-term BeAT-HF dataMINNEAPOLIS, Dec. 26, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the U.S. Food and Drug Administration (FDA) has approved revised Instructions For Use (IFU) for Barostim incorporating key long-term clinical data from the BeAT-HF randomized clinical trial. “We are very pleased to receive this important validat

Yahoo | December 26, 2023

CVRx (CVRX) Is Up 10.17% in One Week: What You Should Know

Does CVRx (CVRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Yahoo | December 18, 2023

CVRx (CVRX) is on the Move, Here's Why the Trend Could be Sustainable

CVRx (CVRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Yahoo | December 8, 2023

Read More 'CVRX' Stories Here

CVRX Price Returns

1-mo -9.22%
3-mo -13.29%
6-mo 41.16%
1-year 110.38%
3-year N/A
5-year N/A
YTD -34.22%
2023 71.34%
2022 50.04%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!